RU97102050A - HETEROCYCLIC ANTAGONISTS OF TACHIKININ RECEPTORS - Google Patents

HETEROCYCLIC ANTAGONISTS OF TACHIKININ RECEPTORS

Info

Publication number
RU97102050A
RU97102050A RU97102050/04A RU97102050A RU97102050A RU 97102050 A RU97102050 A RU 97102050A RU 97102050/04 A RU97102050/04 A RU 97102050/04A RU 97102050 A RU97102050 A RU 97102050A RU 97102050 A RU97102050 A RU 97102050A
Authority
RU
Russia
Prior art keywords
tachikinin
receptors
compound
antagonists
heterocyclic
Prior art date
Application number
RU97102050/04A
Other languages
Russian (ru)
Other versions
RU2151769C1 (en
Inventor
Стефен Чо Сунг-Йонг
Денсмор Копп Джеймс
Орерренио Гинах Франсиз
Джо Хансен Гай
Артур Хипскайнд Филип
Юджин Хафф Брет
Джон Мартинелли Майкл
Александр Стазак Майкл
Вилльям Тарп-Тэйлор Роджер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of RU97102050A publication Critical patent/RU97102050A/en
Application granted granted Critical
Publication of RU2151769C1 publication Critical patent/RU2151769C1/en

Links

Claims (3)

1. Соединение тригидрат дигидрохлорида (R)-3-(1H-индол-3-ил)-1-[N-(2-метоксибензил)ацетиламино] -2-[N-(2-(4-пиперидин-1-ил)пиперидин-1-ил)амино] пропана.1. The compound dihydrochloride trihydrate (R) -3- (1H-indol-3-yl) -1- [N- (2-methoxybenzyl) acetylamino] -2- [N- (2- (4-piperidin-1-yl) ) piperidin-1-yl) amino] propane. 2. Фармацевтический состав, содержащий в качестве активного ингредиента соединение по п. 1, в сочетании с одним или несколькими фармацевтически приемлемыми носителями, разбавителями или эксципиентами. 2. A pharmaceutical composition containing, as an active ingredient, a compound according to claim 1, in combination with one or more pharmaceutically acceptable carriers, diluents or excipients. 3. Соединение по п. 1 для применения при лечении или предупреждения состояния, ассоциируемого с избытком тахикининов. 3. The compound of claim 1 for use in the treatment or prevention of a condition associated with an excess of tachykinins.
RU97102050/04A 1994-07-12 1995-06-30 (r)-3-(1h-indole-3-yl)-1-[n-(2-methoxybenzyl)acetylamino]-2- -[n-(2-(4-piperidine-1-yl)piperidine-1-yl)acetyl)amino]propane dihydrochloride trihydrate and pharmaceutical composition RU2151769C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27170894A 1994-07-12 1994-07-12
US08/271,708 1994-07-12

Publications (2)

Publication Number Publication Date
RU97102050A true RU97102050A (en) 1999-03-10
RU2151769C1 RU2151769C1 (en) 2000-06-27

Family

ID=23036729

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97102050/04A RU2151769C1 (en) 1994-07-12 1995-06-30 (r)-3-(1h-indole-3-yl)-1-[n-(2-methoxybenzyl)acetylamino]-2- -[n-(2-(4-piperidine-1-yl)piperidine-1-yl)acetyl)amino]propane dihydrochloride trihydrate and pharmaceutical composition

Country Status (25)

Country Link
US (1) US5530009A (en)
EP (1) EP0693489B1 (en)
JP (1) JPH10502640A (en)
CN (1) CN1067067C (en)
AT (1) ATE205491T1 (en)
AU (1) AU688072B2 (en)
BR (1) BR9508375A (en)
CA (1) CA2194471C (en)
CO (1) CO4410196A1 (en)
CZ (1) CZ288434B6 (en)
DE (1) DE69522619T2 (en)
DK (1) DK0693489T3 (en)
ES (1) ES2163475T3 (en)
FI (1) FI970107A (en)
HU (1) HUT77948A (en)
IL (1) IL114474A (en)
MX (1) MX9700271A (en)
NO (1) NO309651B1 (en)
NZ (1) NZ289652A (en)
PL (1) PL180866B1 (en)
PT (1) PT693489E (en)
RU (1) RU2151769C1 (en)
TR (1) TR199500844A1 (en)
WO (1) WO1996001819A1 (en)
ZA (1) ZA955639B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
AU5966096A (en) * 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
CA2203424A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
WO1997023455A1 (en) * 1995-12-21 1997-07-03 Eli Lilly And Company Processes for preparing non-peptidyl tachykinin receptor antagonists
CA2247822A1 (en) * 1996-03-11 1997-09-18 Smriti Iyengar Methods of treating or preventing interstitial cystitis
WO1998043639A1 (en) 1997-04-03 1998-10-08 Eli Lilly And Company Methods of treating bone loss
WO1998052890A1 (en) * 1997-05-21 1998-11-26 Eli Lilly And Company 3-arylpropylamino neuropeptide y receptor antagonists
TR200000291T2 (en) 1997-08-06 2000-07-21 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists.
BR9811819A (en) * 1997-08-06 2000-08-15 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists
NO316757B1 (en) 1998-01-28 2004-04-26 Baker Hughes Inc Device and method for remote activation of a downhole tool by vibration
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
DK1246806T3 (en) 1999-11-03 2008-06-16 Amr Technology Inc Aryl and heteroaryl-substituted tetrahydroisoquinolines and their use in blocking the reuptake of norepinephrine, dopsmin and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
EP1299393A2 (en) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (en) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (en) 2007-01-10 2014-12-31 Msd Italia Srl Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (en) 2008-06-04 2010-07-28 Bristol Myers Squibb Co CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (en) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (en) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション Insulin-like growth factor 1 receptor inhibitor
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (en) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Novel compounds that are ERK inhibitors
BR112015012295A8 (en) 2012-11-28 2023-03-14 Merck Sharp & Dohme USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER
MX2015008196A (en) 2012-12-20 2015-09-16 Merck Sharp & Dohme Substituted imidazopyridines as hdm2 inhibitors.
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3367985D1 (en) * 1982-09-18 1987-01-15 Lillywhites Cantabrian Ltd Display unit
US5331089A (en) 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5182282A (en) * 1989-04-28 1993-01-26 Roussel Uclaf 4-Benzyl-1H-indole derivatives
AU687754B2 (en) 1990-08-31 1998-03-05 Warner-Lambert Company Tachykinin antagonists
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676053B1 (en) * 1991-05-03 1993-08-27 Sanofi Elf NOVEL DIALKYLENEPIPERIDINO COMPOUNDS AND THEIR ENANTIOMERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2676055B1 (en) * 1991-05-03 1993-09-03 Sanofi Elf AMINO POLYCYCLIC COMPOUNDS AND THEIR ENANTIOMERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
EP0919245A3 (en) 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
FR2696178B1 (en) 1992-09-30 1994-12-30 Sanofi Elf Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them.
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
EP0686629A3 (en) * 1994-06-10 1999-02-10 Eli Lilly And Company Cyclohexyl tachykinine receptor antagonists

Similar Documents

Publication Publication Date Title
RU97102050A (en) HETEROCYCLIC ANTAGONISTS OF TACHIKININ RECEPTORS
LU93229I2 (en) "Pitolisant and its pharmaceutically acceptable salts, such as hydrochloride"
CO4410196A1 (en) TACHYCIN RECIPIENT HETERO-CYCLICAL ANTAGONISTS
CZ305838B6 (en) N-(2-arylethyl)benzylamines as 5-HT6 receptor antagonists
NO20033732L (en) N-substituted non-aryl heterocyclic NMDA / NR2B antagonists, and pharmaceutical compositions comprising such compounds.
EA200200571A1 (en) NEW COMPOSITION AND ITS APPLICATION
IE901051L (en) Use of indole derivatives as pharmaceuticals
WO1994001407A3 (en) Indole and indene derivatives as pla2 and lipoxygenase inhibitors
DK0765314T3 (en) Benzoheterocyclic derivatives which can be used as vasopressin or oxytocin modulators
YU47396A (en) 2-acylamino propanamines and formulations containing them
DK0531410T3 (en) (+) - alpha- (2,3-Demethoxyphenyl) -1- (2- (4-fluorophenyl) ethyl) -4-piperidinemethanol
FI921997A (en) N- (1- (2-CARBOXYTHYL) CYCLOALKYL-CARBONYL) BETA-ALANINE DERIVATIVES FOR PHARMACEUTICAL BRUK.
WO2003006016A3 (en) Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
FI963083A (en) Treatment of normotensive glaucoma with angiotensin II antagonists
WO1999009025A3 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
DK1230236T3 (en) Compound with growth hormone releasing properties
DK0812831T3 (en) Benzimidazole derivatives and their use as antagonists of corticotropin releasing factor
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
EA200400253A1 (en) APPLICATION OF BIBN4096BS COMPOUND IN COMBINATION WITH OTHER MEDICINAL AGENTS AGAINST MIGRAINE FOR THE TREATMENT OF MIGRAIN
ATE277901T1 (en) SUBSTITUTED PYRROLIDINE 2,3,4-TRION DERIVATIVES ACTIVE AS NMDA RECEPTOR ANTAGONISTS
FI970746A (en) N- (2-pyrrolidinyl-1) -1-phenylethyl) acetamides as kappa receptor antagonists
CA2278057A1 (en) Tachykinin antagonists
SE9302218D0 (en) NEW USE
DK0896822T3 (en) 4-Aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists
ATE166229T1 (en) ANTITUSSIVE